• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Pioneer Floating Rate

Pioneer Floating Rate

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Hengrui Therapeutics Inc. Announces $100 Million Investment from HR Bio Holdings Ltd. for Global Clinical Development

    Hengrui Therapeutics Inc. Announces $100 Million Investment from HR Bio Holdings Ltd. for Global Clinical Development

  2. PENTAX Medical Appoints Dr. Hudson Garrett, Global Chief Clinical Officer

    PENTAX Medical Appoints Dr. Hudson Garrett, Global Chief Clinical Officer

  3. Kiadis Pharma Appoints PCT as its Contract Manufacturing Organization in the United States

    Kiadis Pharma Appoints PCT as its Contract Manufacturing Organization in the United States

  4. Entreprenörskapsforum: Anglo-Saxon countries outperform EU in entrepreneurship

    Entreprenörskapsforum: Anglo-Saxon countries outperform EU in entrepreneurship

  5. Fear Factor: Study Shows a New Genetic Candidate for Treating PTSD

    Fear Factor: Study Shows a New Genetic Candidate for Treating PTSD

  6. Internet Society Elects New Chair; Seats New Board Members at Annual General Meeting

    Internet Society Elects New Chair; Seats New Board Members at Annual General Meeting

  7. Veristat Strengthens Statistical Consulting and Adaptive Design Trial Expertise

    Veristat Strengthens Statistical Consulting and Adaptive Design Trial Expertise

  8. CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases

    CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases

  9. True North’s Lead Product Candidate, TNT009, Demonstrates High Response Rates and Rapid Onset of Action in Interim Clinical Data in Patients with Cold Agglutinin Disease (CAD)

    True North’s Lead Product Candidate, TNT009, Demonstrates High Response Rates and Rapid Onset of Action in Interim Clinical Data in Patients with Cold Agglutinin Disease (CAD)

  10. Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association

    Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.